Tredaptive 2 000 mg/ 40 mg приложен едновременно със симвастатин в сравнение със самостоятелното приложение на симвастатин или Tredaptive 2 000 mg/ 40 mg за 12 седмици значително понижава LDL- C (- 47, 9%, - 37, 0%, - 17, 0%), TG (съответно - 33, 3%, - 14, 7%, - 21, 6%), apo B (съответно - 41, 0%, - 28, 8%, - 17, 1%), и TC (съответно - 29, 6%, - 24, 9%, - 9, 1%), както и LDL- C:
Pacientams, vartojusiems 2000 mg/ 40 mg Tredaptive (2000 mg/ 40 mg) kartu su simvastatinu, palyginti su tiriamaisiais, kurie vartojo vien Tredaptive (2000 mg/ 40 mg) arba vien simvastatino 12 savaičių, kraujyje reikšmingai sumažėjo MTL- C (atitinkamai - 47, 9%, - 37, 0%, - 17, 0%), TG (atitinkamai - 33, 3%, - 14, 7%, - 21, 6%), apo B (atitinkamai - 41, 0%, - 28, 8%, - 17, 1%) ir BC (atitinkamai - 29, 6%, - 24, 9%, - 9, 1%), taip pat MTL- C: DTL- C (atitinkamai - 57, 1%, - 39, 8%, - 31, 2%), neDTL- C (atitinkamai - 45, 8%, - 33, 4%, - 18, 1%) ir BC: DTL- C (atitinkamai - 43, 0%, - 28, 0%, - 24, 9%) kiekis bei reikšmingai padidėjo DTL- C (atitinkamai 27, 5%, 6, 0%, 23, 4%) kiekis.